| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase 3 trial of bevacizumab in ovarian cancer.
|
N Engl J Med
|
2011
|
8.63
|
|
2
|
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
|
J Clin Oncol
|
2009
|
6.56
|
|
3
|
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
|
J Clin Oncol
|
2006
|
4.92
|
|
4
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
5
|
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
|
J Clin Oncol
|
2010
|
3.46
|
|
6
|
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
|
J Natl Cancer Inst
|
2013
|
3.46
|
|
7
|
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
|
Nat Genet
|
2013
|
3.42
|
|
8
|
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
|
J Clin Oncol
|
2011
|
3.06
|
|
9
|
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
|
J Natl Cancer Inst
|
2004
|
2.79
|
|
10
|
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
|
J Clin Oncol
|
2011
|
2.56
|
|
11
|
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
|
J Clin Oncol
|
2010
|
2.54
|
|
12
|
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
|
Int J Gynecol Cancer
|
2011
|
2.09
|
|
13
|
Surgery for relapsed ovarian cancer: when should it be offered?
|
Curr Oncol Rep
|
2012
|
2.08
|
|
14
|
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
|
J Clin Oncol
|
2005
|
1.99
|
|
15
|
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
|
J Natl Cancer Inst
|
2006
|
1.86
|
|
16
|
Intraperitoneal chemotherapy in ovarian cancer remains experimental.
|
J Clin Oncol
|
2006
|
1.73
|
|
17
|
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
|
Nat Commun
|
2013
|
1.73
|
|
18
|
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
|
J Clin Oncol
|
2010
|
1.71
|
|
19
|
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
|
J Clin Oncol
|
2009
|
1.68
|
|
20
|
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
|
Gynecol Oncol
|
2013
|
1.61
|
|
21
|
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
|
Breast Cancer Res Treat
|
2010
|
1.60
|
|
22
|
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
|
Support Care Cancer
|
2004
|
1.56
|
|
23
|
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
|
Ann Surg Oncol
|
2006
|
1.54
|
|
24
|
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.53
|
|
25
|
Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer.
|
Onkologie
|
2010
|
1.45
|
|
26
|
Borderline tumors of the ovary: clinical course and prognostic factors.
|
Onkologie
|
2012
|
1.42
|
|
27
|
Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience.
|
Onkologie
|
2012
|
1.42
|
|
28
|
Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
|
Onkologie
|
2012
|
1.40
|
|
29
|
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2010
|
1.40
|
|
30
|
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
|
Eur J Cancer
|
2009
|
1.38
|
|
31
|
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
|
Gynecol Oncol
|
2013
|
1.36
|
|
32
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
33
|
Gynecologic cancers in pregnancy: guidelines of an international consensus meeting.
|
Int J Gynecol Cancer
|
2009
|
1.35
|
|
34
|
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
|
J Clin Oncol
|
2010
|
1.33
|
|
35
|
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2011
|
1.32
|
|
36
|
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
|
J Pathol
|
2010
|
1.28
|
|
37
|
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
|
Gynecol Oncol
|
2005
|
1.25
|
|
38
|
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
|
J Natl Cancer Inst
|
2004
|
1.15
|
|
39
|
Bevacizumab in the treatment of ovarian cancer.
|
Adv Ther
|
2012
|
1.12
|
|
40
|
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
|
Breast Cancer Res
|
2009
|
1.12
|
|
41
|
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
|
Ann Surg Oncol
|
2006
|
1.12
|
|
42
|
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
|
Gynecol Oncol
|
2009
|
1.11
|
|
43
|
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
|
Int J Gynecol Cancer
|
2011
|
1.09
|
|
44
|
Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis.
|
Am J Obstet Gynecol
|
2013
|
1.07
|
|
45
|
Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.
|
Gynecol Oncol
|
2011
|
1.02
|
|
46
|
NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
|
Cancer Res
|
2008
|
1.02
|
|
47
|
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
|
J Clin Oncol
|
2010
|
1.01
|
|
48
|
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
|
Ann Surg Oncol
|
2010
|
0.99
|
|
49
|
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
|
Hum Genet
|
2013
|
0.99
|
|
50
|
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
|
Eur J Clin Pharmacol
|
2011
|
0.98
|
|
51
|
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
|
Ann Surg Oncol
|
2011
|
0.97
|
|
52
|
Mediation analysis of the relationship between institutional research activity and patient survival.
|
BMC Med Res Methodol
|
2014
|
0.96
|
|
53
|
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
|
J Clin Oncol
|
2006
|
0.96
|
|
54
|
Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
|
Cancer
|
2009
|
0.96
|
|
55
|
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
|
Gynecol Oncol
|
2012
|
0.95
|
|
56
|
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
|
Gynecol Oncol
|
2006
|
0.94
|
|
57
|
Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications.
|
Int J Gynecol Cancer
|
2010
|
0.94
|
|
58
|
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
|
J Clin Oncol
|
2009
|
0.94
|
|
59
|
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.92
|
|
60
|
Specialized pathology review in patients with ovarian cancer: results from a prospective study.
|
Int J Gynecol Cancer
|
2013
|
0.91
|
|
61
|
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.
|
Support Care Cancer
|
2010
|
0.90
|
|
62
|
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
|
Cancer Res
|
2013
|
0.89
|
|
63
|
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
|
Gynecol Oncol
|
2006
|
0.89
|
|
64
|
Differences in the receptor status between primary and recurrent breast cancer--the frequency of and the reasons for discordance.
|
Oncology
|
2013
|
0.89
|
|
65
|
The changing landscape of therapeutic strategies for recurrent ovarian cancer.
|
Future Oncol
|
2012
|
0.89
|
|
66
|
The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence.
|
Curr Opin Oncol
|
2005
|
0.89
|
|
67
|
Prognostic factors for complete debulking in first- and second-line ovarian cancer.
|
Int J Gynecol Cancer
|
2009
|
0.89
|
|
68
|
BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
|
Onkologie
|
2007
|
0.86
|
|
69
|
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
|
Expert Rev Anticancer Ther
|
2010
|
0.86
|
|
70
|
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
|
Gynecol Oncol
|
2010
|
0.85
|
|
71
|
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).
|
Int J Gynecol Cancer
|
2014
|
0.84
|
|
72
|
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
|
Gynecol Oncol
|
2012
|
0.83
|
|
73
|
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
|
Int J Gynecol Cancer
|
2015
|
0.82
|
|
74
|
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
|
Cancer Immunol Res
|
2014
|
0.82
|
|
75
|
Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
|
Expert Rev Anticancer Ther
|
2010
|
0.82
|
|
76
|
Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.82
|
|
77
|
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
|
Gynecol Oncol
|
2005
|
0.82
|
|
78
|
Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer.
|
Int J Gynecol Cancer
|
2016
|
0.82
|
|
79
|
Synchronous ovarian and endometrial cancer--an international multicenter case-control study.
|
Int J Gynecol Cancer
|
2014
|
0.81
|
|
80
|
Abagovomab for ovarian cancer.
|
Expert Opin Biol Ther
|
2011
|
0.80
|
|
81
|
Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
|
Gynecol Oncol
|
2006
|
0.80
|
|
82
|
Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany.
|
Onkologie
|
2013
|
0.80
|
|
83
|
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
|
Histopathology
|
2013
|
0.80
|
|
84
|
Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
|
Int J Gynecol Cancer
|
2009
|
0.80
|
|
85
|
Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
|
Virchows Arch
|
2009
|
0.80
|
|
86
|
No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group.
|
Int J Gynecol Pathol
|
2008
|
0.79
|
|
87
|
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
|
Int J Gynecol Cancer
|
2010
|
0.79
|
|
88
|
Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
|
Crit Rev Oncol Hematol
|
2006
|
0.79
|
|
89
|
Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activity.
|
Clin Cancer Res
|
2012
|
0.79
|
|
90
|
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
|
Invest New Drugs
|
2013
|
0.78
|
|
91
|
ESGO statement on cervical cancer vaccination.
|
Int J Gynecol Cancer
|
2007
|
0.77
|
|
92
|
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.
|
Mol Nutr Food Res
|
2014
|
0.77
|
|
93
|
Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany.
|
Onkologie
|
2005
|
0.77
|
|
94
|
Implementation of robot-assisted gynecologic surgery for patients with low and high BMI in a German gynecological cancer center.
|
Arch Gynecol Obstet
|
2014
|
0.77
|
|
95
|
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
|
Int J Gynecol Cancer
|
2015
|
0.77
|
|
96
|
Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.
|
Int J Gynecol Cancer
|
2017
|
0.77
|
|
97
|
Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
|
Crit Rev Oncol Hematol
|
2010
|
0.76
|
|
98
|
Role of cytoreductive surgery in recurrent ovarian cancer.
|
Expert Rev Anticancer Ther
|
2009
|
0.76
|
|
99
|
Response.
|
J Natl Cancer Inst
|
2014
|
0.75
|
|
100
|
In reply: response to Sammartino et al.
|
Curr Oncol Rep
|
2013
|
0.75
|
|
101
|
Mammographic screening: no reliable supporting evidence?
|
Lancet
|
2002
|
0.75
|
|
102
|
Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study.
|
Support Care Cancer
|
2014
|
0.75
|
|
103
|
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.
|
Int J Gynecol Cancer
|
2014
|
0.75
|
|
104
|
Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma.
|
Int J Gynecol Cancer
|
2009
|
0.75
|
|
105
|
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
106
|
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
107
|
Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.
|
Int J Gynecol Cancer
|
2013
|
0.75
|
|
108
|
Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.
|
Hum Immunol
|
2010
|
0.75
|
|
109
|
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.75
|
|
110
|
European Surgical Education and Training in Gynecologic Oncology: The impact of an Accredited Fellowship.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
111
|
Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
112
|
Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
|
Future Oncol
|
2008
|
0.75
|
|
113
|
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
114
|
The sandwich technique of diaphragmatic stripping or full-thickness resection for advanced ovarian cancer: how to keep it short and simple.
|
Int J Gynecol Cancer
|
2015
|
0.75
|
|
115
|
Surgery for recurrent ovarian cancer.
|
Womens Health (Lond Engl)
|
2011
|
0.75
|
|
116
|
The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.
|
Int J Gynecol Cancer
|
2015
|
0.75
|